ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,321 to 4,340 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Retrospective vs Prospective: deaths from any cause50 of 991

15 of 489

2.0 points

-0.3 to 3.9

1,480NCT03426124

An International Pulmonary Embolism Registry Using EKOS

Retrospective vs Prospective: serious adverse events100 of 991

39 of 489

2.1 points

-1.1 to 5.0

1,480NCT03426124

An International Pulmonary Embolism Registry Using EKOS

ADG20 IM - Cohort B vs Placebo IM - Cohort B: Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PrEP)12 of 752

40 of 728

-3.9 points

-5.9 to -2.0

1,480NCT04859517

Evaluation of ADG20 for the Prevention of COVID-19

ADG20 IM - Cohort B vs Placebo IM - Cohort B: Percentage of Participants With Asymptomatic SARS-CoV-2 Infection as Determined by Serology (PrEP)10 of 752

18 of 728

-1.1 points

-2.7 to 0.3

1,480NCT04859517

Evaluation of ADG20 for the Prevention of COVID-19

Restrictive Fluids vs Liberal Fluids: Initiation of Renal Replacement Therapy24 of 738

24 of 738

0.0 points

-1.9 to 1.9

1,476NCT03434028

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

IV Abatacept vs SC Abatacept: serious adverse events206 of 731

199 of 744

1.4 points

-3.1 to 6.0

1,475NCT00559585

Methotrexate-Inadequate Response Study

Retrospective vs Prospective: Number of Patients Needing an IVC Filter Placement50 of 991

20 of 483

0.9 points

-1.6 to 3.0

1,474NCT03426124

An International Pulmonary Embolism Registry Using EKOS

Arm I (Chemotherapy) vs Arm II (Chemotherapy, Bevacizumab): serious adverse events424 of 738

563 of 735

-19.1 points

-23.8 to -14.4

1,473NCT00324805

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: Number of Participants With an Unplanned Fracture-Related Reoperation118 of 734

115 of 738

0.5 points

-3.2 to 4.2

1,472NCT03385304

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death5 of 978

5 of 492

-0.5 points

-1.9 to 0.4

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Strokes, Transient Ischemic Attacks, Non-central Nervous System Systemic Embolisms, Myocardial Infarctions and All-cause Mortality6 of 978

6 of 492

-0.6 points

-2.1 to 0.4

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With All-cause Mortality5 of 978

3 of 492

-0.1 points

-1.3 to 0.7

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Strokes and Non-central Nervous System Systemic Embolisms2 of 978

3 of 492

-0.4 points

-1.6 to 0.3

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Non-central Nervous System Systemic Embolisms0 of 978

1 of 492

-0.2 points

-1.1 to 0.2

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Strokes2 of 978

2 of 492

-0.2 points

-1.3 to 0.4

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Cardiovascular Deaths4 of 978

2 of 492

0.0 points

-1.1 to 0.7

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Myocardial Infarctions1 of 978

1 of 492

-0.1 points

-1.0 to 0.4

1,470NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Denosumab 60 mg Q6M vs Placebo: Number of Participants With Any Fracture Through Month 3638 of 734

53 of 734

-2.0 points

-4.6 to 0.4

1,468NCT00089674

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Denosumab 60 mg Q6M vs Placebo: Number of Participants With Any Fracture Through Month 2432 of 734

45 of 734

-1.8 points

-4.1 to 0.5

1,468NCT00089674

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Alteplase Active Control Group vs Tenecteplase Treatment Group: deaths from any cause44 of 736

34 of 732

1.3 points

-1.0 to 3.7

1,468NCT04915729

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=217"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=217

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03426124-deaths",
        "title": "Retrospective vs Prospective: deaths from any cause",
        "summary": "50 of 991 against 15 of 489; risk difference 2.0 points, 95% interval -0.3 to 3.9; NCT03426124, An International Pulmonary Embolism Registry Using EKOS",
        "record": "/library/comparisons/NCT03426124-deaths",
        "nct_id": "NCT03426124",
        "kind": "deaths",
        "participants": 1480,
        "risk_difference": {
          "value": 0.019779240155262393,
          "lower": -0.002947264243403018,
          "upper": 0.03933928676641793
        },
        "group_1": "50 of 991",
        "group_2": "15 of 489",
        "difference": "2.0 points",
        "interval": "-0.3 to 3.9",
        "trial_title": "An International Pulmonary Embolism Registry Using EKOS"
      },
      {
        "id": "NCT03426124-sae",
        "title": "Retrospective vs Prospective: serious adverse events",
        "summary": "100 of 991 against 39 of 489; risk difference 2.1 points, 95% interval -1.1 to 5.0; NCT03426124, An International Pulmonary Embolism Registry Using EKOS",
        "record": "/library/comparisons/NCT03426124-sae",
        "nct_id": "NCT03426124",
        "kind": "serious-adverse-events",
        "participants": 1480,
        "risk_difference": {
          "value": 0.021153572335064666,
          "lower": -0.011232778371752385,
          "upper": 0.050279717863004586
        },
        "group_1": "100 of 991",
        "group_2": "39 of 489",
        "difference": "2.1 points",
        "interval": "-1.1 to 5.0",
        "trial_title": "An International Pulmonary Embolism Registry Using EKOS"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=218",
  "request_id": "3FTE2yCHwn0HCLd0"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?